A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval
- 23 December 2023
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 110 (4) , 295-296
Abstract
Cisplatin-based combos have become first-line treatment regimens in standard of care because of their high overall survival improvement. Despite being the first-line therapy, due to its side effects, roughly half of all patients suffering from Metastatic urothelial cancer are ineligible for it. To address this issue, scientists have been developing highly specific antibody-drug conjugates to address this issue. For locally advanced or metastatic bladder cancer, a combination of Padcev (enfortumab vedotin-ejfv) with pembrolizumab (Keytruda) has been authorized by the FDA as a first-line treatment and has shown promising outcomes in patients with metastatic urothelial carcinoma who are ineligible for cisplatin-based combinations.Keywords
This publication has 11 references indexed in Scilit:
- BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patientsTumori Journal, 2022
- A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)Tumori Journal, 2022
- Reasons for lack of treatment in patients with locally advanced, unresectable or metastatic urothelial carcinomaActa Oncologica, 2022
- The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial CarcinomaEuropean Urology, 2022
- Metastatic urothelial carcinomaCancer Cell, 2021
- FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaClinical Cancer Research, 2021
- Targeting cancer with antibody-drug conjugates: Promises and challengesmAbs, 2021
- Enfortumab Vedotin Antibody–Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer ModelsCancer Research, 2016
- Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificityCellular and Molecular Life Sciences, 2014
- Defining “cisplatin ineligible” patients with metastatic bladder cancer.Journal of Clinical Oncology, 2011